Hip is a technology company.
Hip has raised $12.0M across 1 funding round.
Hip has raised $12.0M in total across 1 funding round.
Hip Innovation Technology, LLC (HIT) is a privately held medical technology company founded in 2011, specializing in orthopedic device solutions, particularly innovative hip implants.[1][2] Its lead product, the Reverse Hip Replacement System (Reverse HRS), is a unique implant design aimed at optimizing existing hip systems while addressing unmet clinical needs in Total Hip Arthroplasty (THA), currently in clinical trials and not yet available for sale.[1][2] HIT serves patients and healthcare providers by advancing quality of life and care through differentiated features like state-of-the-art surgical instruments and a robust intellectual property portfolio exceeding 160 issued patents and 130 pending applications, protected through 2030.[1]
Headquartered in Boca Raton, Florida, as a subsidiary of Joint Innovation Technology, LLC, HIT focuses on breakthrough technologies in orthopedics with over four years of rigorous R&D.[1] This positions it in the growing medtech sector, emphasizing product differentiation amid rising demand for advanced joint replacement solutions.[1][2]
Hip Innovation Technology, LLC was formed in 2011 as a privately held entity dedicated to orthopedic innovations.[1][2] While specific founders are not detailed in available sources, the company's early commitment centered on developing market-leading devices, culminating in the Reverse HRS after rational design to enhance marketed hip systems and solve clinical gaps.[1] Pivotal moments include over four years of world-class device design, R&D, and building an extensive IP portfolio with 160+ issued patents, 130+ pending applications, and 61 design registrations.[1]
Corporate evolution includes establishing headquarters in Boca Raton, Florida, and operating as a subsidiary of Joint Innovation Technology, LLC, with ongoing clinical trials marking progress toward commercialization.[1][2]
HIT stands out in orthopedics through targeted innovations:
These elements provide competitive edges in clinical outcomes and market entry.[1]
HIT rides the trend of advanced orthopedic implants amid rising THA demand due to aging populations and active lifestyles, where unmet needs like implant stability and longevity persist.[1] Timing aligns with medtech's shift toward innovative designs and IP-protected breakthroughs, as traditional systems face limitations in addressing complications.[1][2]
Market forces favoring HIT include regulatory progress via clinical trials and a strong patent moat, enabling differentiation in a competitive field.[1] It influences the ecosystem by advancing THA standards, potentially reducing revision surgeries and improving care efficiency, while complementing digital tools like mixed-reality platforms in hip surgery.[1][5]
HIT's path forward hinges on Reverse HRS clinical trial success and FDA clearance, potentially launching a family of implants with superior features by late 2020s.[1] Trends like personalized orthopedics, additive manufacturing integration (e.g., HIP processing for implants), and digital surgery navigation will amplify its momentum, expanding addressable markets.[1][3][4][5]
Influence may evolve from developer to market leader if commercialization scales, tying back to its 2011 mission of transformative orthopedic solutions that elevate patient outcomes.[1][2]
Hip has raised $12.0M in total across 1 funding round.
Hip's investors include Magenta Venture Partners.
Hip has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $12.0M Series A | Magenta Venture Partners |